IMMX — Immix Biopharma, Inc.
Is IMMX overbought or oversold? Here is the current MarketMoodz read.
Immix Biopharma, Inc. (IMMX) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $7.48. The rating moved from Oversold to Strong Oversold on November 17, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$7.48
- Last changeMoved from Oversold to Strong Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Immix Biopharma, Inc. (IMMX) appears to be a pipeline-focused small-cap biopharma with limited public filing detail available for assessment. The near-term outlook is driven by binary clinical/regulatory and financing events; prevailing market risk-on sentiment could provide short-lived upward momentum, but convertible-debt and mid‑cap financing trends increase the probability of dilution that would weigh on equity value. Without clear disclosure on cash runway, revenues or imminent catalysts, the stock is likely to trade range-bound with episodes of high volatility until more definitive clinical, commercial or financing information becomes available.
Key factors
- Limited public filing visibility (no recent EDGAR comps provided) increases uncertainty around cash runway and near-term financing needs
- Small-cap biopharma profile with typical binary, pipeline-driven upside tied to clinical/regulatory catalysts
- Market risk-on tone and retail optimism around upcoming releases could create short-term positive flows
- Sector readthroughs: convertible-debt and financing dynamics in mid‑cap biotech raise potential dilution/hedging pressure
- Industry trends (shift to specialty/outpatient channels) could provide commercial opportunities if relevant assets/partnerships exist
- Large-cap pharma defensive flows may divert some risk-averse institutional capital away from small biotech names
Risks
- Clinical or regulatory setbacks for any pipeline asset, which would likely cause sharp share-price moves
- Dilution risk from equity or convertible financings if cash runway is limited
- Low liquidity and small-float volatility magnifying price swings on news or social chatter
- Lack of recent, detailed public financial disclosures impeding accurate assessment of liquidity and burn rate
- Competitive pressures from larger pharma or alternative therapeutics in the same indications
- Reimbursement or commercialization execution challenges if/when products approach market
See today's live rating, score and targets
Members see the live hourly rating for IMMX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.